AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6869546 — intervention group
Group type: COMPARATOR
Intervention: Meals B and C (unassociated with generation of breath hydrogen)
Number of subjects: 6
Study 6869546 — intervention group
Group type: EXPERIMENTAL
Intervention: All meals (A, B, and C)
Number of subjects: 6
Study 31933341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching (DY)
Number of subjects: 11
Study 31933341 — intervention group
Group type: COMPARATOR
Intervention: Static stretching (ST)
Number of subjects: 11
Study 31933341 — intervention group
Group type: COMPARATOR
Intervention: Static + dynamic stretching (ST+DY)
Number of subjects: 11
Study 31933341 — intervention group
Group type: COMPARATOR
Intervention: Dynamic + static stretching (DY+ST)
Number of subjects: 11
Study 29389835 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg (oral) SAL
Number of subjects: 14
Study 29389835 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 μg (inhaled) SAL
Number of subjects: 14
Study 29389835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27888180 — intervention group
Group type: EXPERIMENTAL
Intervention: New York University Caregiver Intervention (NYUCI)
Number of subjects: 200
Study 27888180 — intervention group
Group type: COMPARATOR
Intervention: Resources for Enhancing Alzheimer's Caregivers Health (REACH)
Number of subjects: 200
Study 25412911 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Surveillance (AS)
Number of subjects: 3169
Study 25412911 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful Waiting (WW)
Number of subjects: 3169
Study 25412911 — intervention group
Group type: COMPARATOR
Intervention: Hormonal treatment, Radiotherapy, Operation
Number of subjects: 3169
Study 22659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 67
Study 22659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 67
Study 22659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive defusion (across both CBT and ACT)
Number of subjects: 67
Study 22659156 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity (across both CBT and ACT)
Number of subjects: 67
Study 20042444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 microg/kg DDAVP
Number of subjects: 22
Study 20042444 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 22
Study 17510908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training newborn hearing screeners to present information about the screening test and to ask questions to check understanding
Number of subjects: 30
Study 17510908 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires sent to screeners to elicit their responses
Number of subjects: 30
Study 16055642 — intervention group
Group type: EXPERIMENTAL
Intervention: Context prime of opposite valence
Number of subjects: 0
Study 16055642 — intervention group
Group type: COMPARATOR
Intervention: Context prime of same valence
Number of subjects: 0
Study 12810176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 20 mg weekly for 84 days
Number of subjects: 200
Study 12810176 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 2.5 mg daily for 84 days
Number of subjects: 200
Study 12810176 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative dose 130 mg or less
Number of subjects: 200
Study 12810176 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial measurements of s-CTX
Number of subjects: 200
Study 12810176 — intervention group
Group type: COMPARATOR
Intervention: No treatment for 168 days
Number of subjects: 200
Study 10589647 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amino acid mixture, 126 mL/h
Number of subjects: 45
Study 10589647 — intervention group
Group type: COMPARATOR
Intervention: Acetated Ringer's solution
Number of subjects: 45
Study 8616532 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamazole 20mg/day for 14 days
Number of subjects: 51
Study 8616532 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium perchlorate 900mg/day for 14 days
Number of subjects: 51
Study 8616532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 51
Study 1817629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg in 0.9% sodium chloride 8 ml
Number of subjects: 51
Study 1817629 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamorphine 5 mg in 0.9% sodium chloride 8 ml with 1:200,000 adrenaline
Number of subjects: 51
Study 1817629 — intervention group
Group type: COMPARATOR
Intervention: 0.375% bupivacaine 8 ml
Number of subjects: 51
Study 7172717 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2.5% phenylephrine hydrochloride
Number of subjects: 22
Study 7172717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 22
Study 30652422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) at 8-10 mg/kg of body weight per day
Number of subjects: 401
Study 30652422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study 30652422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 401
Study 28248693 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg Calcium (CA)
Number of subjects: 51
Study 28248693 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 51
Study 27154593 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat 250 mg single dose
Number of subjects: 89
Study 27154593 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat 800 mg multiple doses (q8 h for up to 7 days)
Number of subjects: 89
Study 27154593 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat 2400 mg/day multiple doses
Number of subjects: 89
Study 27154593 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoralstat (doses ≥400 mg q8 h)
Number of subjects: 89
Study 27154593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 24342144 — intervention group
Group type: EXPERIMENTAL
Intervention: Alvimopan
Number of subjects: 0
Study 23147877 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.25%)
Number of subjects: 35
Study 23147877 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 35
Study 19686003 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory processes during conflictual interactions
Number of subjects: 5
Study 19686003 — intervention group
Group type: COMPARATOR
Intervention: High dispositional self-control
Number of subjects: 5
Study 19686003 — intervention group
Group type: COMPARATOR
Intervention: Immediate response to partner provocations
Number of subjects: 5
Study 19686003 — intervention group
Group type: COMPARATOR
Intervention: Depleted self-regulatory resources
Number of subjects: 5
Study 19686003 — intervention group
Group type: COMPARATOR
Intervention: Bolstered self-regulatory resources via a 2-week training regimen
Number of subjects: 5
Study 17890499 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in perceived stress
Number of subjects: 63
Study 17890499 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate reactivity
Number of subjects: 63
Study 15375811 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted postoperative care based on preoperative risk assessment using the Risk Assessment and Prediction Tool (RAPT) in 50 patients (2001).
Number of subjects: 100
Study 15375811 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted postoperative care in 2001.
Number of subjects: 100
Study 15375811 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (50 patients treated in 2000).
Number of subjects: 100
Study 16235068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-derived prediction equations for skeletal muscle mass
Number of subjects: 72
Study 16235068 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-derived prediction equations applied to validation group
Number of subjects: 72
Study 16235068 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman analysis
Number of subjects: 72
Study 10393145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed at lowering dietary fat intake and increasing physical activity
Number of subjects: 236
Study 10393145 — intervention group
Group type: COMPARATOR
Intervention: Control group (weight-stable)
Number of subjects: 236
Study 10393145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 236
Study 8677539 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic developments for bladder cancer management in the elderly
Number of subjects: 0
Study 8677539 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA‐based screening
Number of subjects: 0
Study 1324534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (3,000 anti-Xa units, one subcutaneous injection)
Number of subjects: 653
Study 1324534 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin (5,000 U, subcutaneously three times a day)
Number of subjects: 653
Study 1324534 — intervention group
Group type: COMPARATOR
Intervention: Low-dose heparin
Number of subjects: 653
Study 1324534 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 653
Study 1324534 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (low molecular weight heparin and low-dose heparin)
Number of subjects: 653
Study 6383491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin 10 mg orally three times daily for at least one year
Number of subjects: 68
Study 6383491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further adjuvant treatment)
Number of subjects: 68
Study 6383491 — intervention group
Group type: EXPERIMENTAL
Intervention: Bestatin treatment
Number of subjects: 68
Study 31660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature test-high patients
Number of subjects: 681
Study 31660791 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I interferon gene signature test-low patients
Number of subjects: 681
Study 30345906 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus nab-paclitaxel
Number of subjects: 902
Study 30345906 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel
Number of subjects: 902
Study 27542350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM) every 30 minutes
Number of subjects: 4612
Study 27542350 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate monitoring (FHRM) less than every hour or not at all
Number of subjects: 4612
Study 27542350 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using a partogram
Number of subjects: 4612
Study 24135557 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab (0.5 mg) injections
Number of subjects: 13
Study 21986189 — intervention group
Group type: EXPERIMENTAL
Intervention: Iso GUM
Number of subjects: 30
Study 21986189 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 30
Study 21986189 — intervention group
Group type: EXPERIMENTAL
Intervention: Reform GUM
Number of subjects: 30
Study 21986189 — intervention group
Group type: COMPARATOR
Intervention: Std GUM
Number of subjects: 30
Study 19248192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole treatment for 3 months
Number of subjects: 58
Study 19248192 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole treatment for 6 months
Number of subjects: 58
Study 17443469 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of macrophage migration inhibitory factor (MIF)
Number of subjects: 145
Study 17443469 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating concentrations of MIF
Number of subjects: 145
Study 17443469 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF levels in meningococcal sepsis
Number of subjects: 145
Study 15673630 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 850
Study 15673630 — intervention group
Group type: COMPARATOR
Intervention: Positive control (not specified)
Number of subjects: 850
Study 15673630 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 850
Study 12478843 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil (group A)
Number of subjects: 54
Study 12478843 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of prostaglandin E1 (PGE1) (group B)
Number of subjects: 54
Study 12478843 — intervention group
Group type: COMPARATOR
Intervention: Intracavernosal injection of PGE1 (group B)
Number of subjects: 54
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for shortness of breath (SOB)
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) for anxiety
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirometry
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum inspiratory pressure (MIP)
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac evaluation
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially correctable causes of dyspnea
Number of subjects: 100
Study 9803048 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of respiratory muscle strength
Number of subjects: 100
Study 7700741 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVIG 750 mg/kg (high dose)
Number of subjects: 162
Study 7700741 — intervention group
Group type: COMPARATOR
Intervention: No RSVIG (control group)
Number of subjects: 162
Study 31003670 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 0
Study 31003670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 0
Study 28550004 — intervention group
Group type: EXPERIMENTAL
Intervention: PhoS app
Number of subjects: 44
Study 28550004 — intervention group
Group type: COMPARATOR
Intervention: Generalized relapse prevention training (Control)
Number of subjects: 44
Study 25827133 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency coblation
Number of subjects: 41
Study 25827133 — intervention group
Group type: COMPARATOR
Intervention: Intramural bipolar cautery
Number of subjects: 41
Study 23061828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 1200 mg/daily
Number of subjects: 1006
Study 21813919 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine L-tartrate (3 g, 2 g L-carnitine/d; n = 8)
Number of subjects: 15
Study 21813919 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 7)
Number of subjects: 15
Study 19403652 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen (tenofovir disoproxil fumarate and efavirenz)
Number of subjects: 143
Study 19403652 — intervention group
Group type: COMPARATOR
Intervention: Three-drug regimen (tenofovir DF, lamivudine, and efavirenz)
Number of subjects: 143
Study 19403652 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-drug regimen (tenofovir DF and efavirenz)
Number of subjects: 143
Study 19403652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 143
Study 16314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129
Study 16314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129
Study 16314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower oil (30% of individual resting energy expenditure for 8 weeks)
Number of subjects: 129
Study 16314877 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 129
Study 15022504 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical medications (antifungals or disinfectants)
Number of subjects: 24
Study 15022504 — intervention group
Group type: COMPARATOR
Intervention: Randomized controlled trials
Number of subjects: 24
Study 11286949 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 3.8 g with Simvastatin 10 mg
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Number of subjects: 210
Study 11286949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam 2.3 g with Simvastatin 20 mg
Number of subjects: 210
Study 9250317 — intervention group
Group type: EXPERIMENTAL
Intervention: Riu stain
Number of subjects: 86
Study 9250317 — intervention group
Group type: COMPARATOR
Intervention: Papanicolaou stain
Number of subjects: 86
Study 8496756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent feedings
Number of subjects: 24
Study 8496756 — intervention group
Group type: COMPARATOR
Intervention: Continuous feedings
Number of subjects: 24
Study 2446091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high dosage, about 700 mg intravenously from the start of anaesthesia to the end of operation)
Number of subjects: 22
Study 2446091 — intervention group
Group type: COMPARATOR
Intervention: Control (no aprotinin)
Number of subjects: 22
Study 2446091 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high dosage)
Number of subjects: 22
Study 29704972 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety behavior after fear extinction
Number of subjects: 0
Study 29704972 — intervention group
Group type: COMPARATOR
Intervention: No safety behavior (control for A and B)
Number of subjects: 0
Study 28317356 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer
Number of subjects: 20
Study 28317356 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Number of subjects: 20
Study 24448850 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Eigenständig werden 5+6' school-based prevention programme
Number of subjects: 2513
Study 24448850 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2513
Study 22872770 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg/d for 7 days
Number of subjects: 185
Study 22872770 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 185
Study 20484178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 180
Study 20484178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 18560140 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-induced movement therapy (CIMT) with modified opposition restriction orthosis (MORO), 5 hours/day, 7 days/week for 8 weeks
Number of subjects: 21
Study 15831644 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography (DSE)
Number of subjects: 24
Study 15831644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic wall thickness (DWT) > 0.6 cm
Number of subjects: 24
Study 15831644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DSE improvement or DWT > 0.8 cm
Number of subjects: 24
Study 15831644 — intervention group
Group type: COMPARATOR
Intervention: DSE alone
Number of subjects: 24
Study 15831644 — intervention group
Group type: EXPERIMENTAL
Intervention: DWT > 0.8 cm
Number of subjects: 24
Study 12906979 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged monitoring with an implantable loop recorder with one-year monitoring
Number of subjects: 60
Study 12906979 — intervention group
Group type: COMPARATOR
Intervention: Conventional testing with external loop recorder, tilt, and electrophysiologic testing
Number of subjects: 60
Study 12906979 — intervention group
Group type: COMPARATOR
Intervention: Crossover from conventional testing to monitoring
Number of subjects: 60
Study 12906979 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring followed by tilt and EP testing
Number of subjects: 60
Study 12906979 — intervention group
Group type: COMPARATOR
Intervention: Conventional testing followed by monitoring
Number of subjects: 60
Study 10485722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg/day) and Vitamin E (400 IU/day)
Number of subjects: 283
Study 10485722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 10485722 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C and E
Number of subjects: 283
Study 8608485 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil (5-FU) at doses ranging from 200-1100 mg/m2/day for 4 days
Number of subjects: 25
Study 8608485 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy with radioactive gold (Au198) seed placement
Number of subjects: 25
Study 1768563 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) alone
Number of subjects: 10
Study 1768563 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) + Indomethacin (75 mg) + Ketotifen (1 mg)
Number of subjects: 10
Study 1768563 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg) + Indomethacin (75 mg)
Number of subjects: 10
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken with 100 ml of water
Number of subjects: 121
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken with 25 ml of water
Number of subjects: 121
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken while recumbent
Number of subjects: 121
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets and capsules taken while standing
Number of subjects: 121
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Small tablets
Number of subjects: 121
Study 6816343 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid forms of medication (suspensions)
Number of subjects: 121